A Phase 1 interventional study of Combined oral contraceptives (COC) and Moxifloxacin 400mg in Healthy Subjects, sponsored by Viatris Innovation GmbH. Completed at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center, randomized, double-blind for cenerimod, open-label for moxifloxacin, placebo- and moxifloxacin-controlled, parallel-group study to investigate the effect of cenerimod on the duration of the QT interval in healthy male and female participants.
Participants will be randomly assigned to one of the 4 treatments: placebo, cenerimod 0.5 mg, cenerimod 4 mg or moxifloxacin.
Participants randomized in one of the cenerimod or placebo groups will receive combined oral contraceptives on Day 1 (i.e., prior to cenerimod or placebo administration, Period 1) and on Day 42 (i.e., 36 days after the stat of cenerimod or placebo, Period 2).
Half of the participants randomized in one of the cenerimod or placebo groups will be enrolled in an accelerated elimination procedure part (Period 3).
Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 1.
Drug: Combined oral contraceptives (COC)
Participants randomized to placebo or cenerimod will receive a single oral dose of levonorgestrel (100 μg) and ethinylestradiol (20 μg) in the morning on Day 42.
Drug: Combined oral contraceptives (COC) · Drug: Cenerimod 0.5 mg · Drug: Cenerimod 4 mg
Participants randomized to cenerimod 0.5 mg will receive a single oral dose in the morning from Day 7 to Day 56.
Drug: Combined oral contraceptives (COC)
Participants randomized to cenerimod 4 mg will receive a single oral dose in the morning from Day 7 to Day 56.
Drug: Combined oral contraceptives (COC)
Participants randomized to moxifloxacin will receive a single oral 400 mg dose in the morning of Day 42.
Drug: Moxifloxacin 400mg
Participants randomized to placebo will receive a single oral dose of placebo in the morning from Day 7 to Day 56.
Drug: Matching Placebo
Participants randomized to cenerimod 0.5 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.
Drug: Cenerimod 0.5 mg · Other: Charcoal, activated
Participants randomized to cenerimod 4 mg in Period 2 will receive 50 g of activated charcoal every 12 hours from Day 57 to Day 67.
Drug: Cenerimod 4 mg · Other: Charcoal, activated
Participants randomized to cenerimod 0.5 mg or 4 mg in Period 2 will receive no treatment (i.e., activated charcoal from Day 57 to Day 67) but will have blood samples taken.
Drug page: Contraceptives, Oral, Combined
A commercially available COC consisting of 0.1mg levonorgestrel and 0.02 mg ethinylestradiol will be used and administered open-label.
Also known as: Levonorgestrel/Ethinylestradiol
A commercially available formulation of moxifloxacin 400 mg will be used and administered open-label. All tablets will be from the same batch.
This will be administered orally as a film-coated tablet in the morning.
Also known as: ACT-334441
This will be administered orally as a film-coated tablet in the morning.
Also known as: ACT-334441
Granules for oral suspension will be used and administered open-label.
Also known as: Carbomix 50g
Cenerimod matching placebo tablets will be administered once daily orally in the morning.
Placebo-corrected, change-from-baseline QTcF (ΔΔQTcF)
ECG variables will be assessed from ECGs extracted in replicates at predefined time points from continuous 24 hour Holter ECG recordings.
Time frame: Day 6, 7, 14, 21, 35, and 56.
Maximum plasma concentration (Cmax): levonorgestrel
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 1 to Day 3; Day 42 to Day 44
Maximum plasma concentration (Cmax): ethinylestradiol
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 1 to Day 3; Day 42 to Day 44
Time to reach Cmax (tmax): levonorgestrel
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 1 to Day 3; Day 42 to Day 44
Time to reach Cmax (tmax): ethinylestradiol
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 1 to Day 3; Day 42 to Day 44
The area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf): levonorgestrel
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 1 to Day 3; Day 42 to Day 44
The area under the plasma concentration-time curve (AUC) from zero to t (AUC0-t): levonorgestrel
Blood samples for determination of PK parameters will be collected at predefined
Time frame: Day 1 to Day 3; Day 42 to Day 44
The area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf): ethinylestradiol
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 1 to Day 3; Day 42 to Day 44
The area under the plasma concentration-time curve (AUC) from zero to t (AUC0-t): ethinylestradiol
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 1 to Day 3; Day 42 to Day 44
Terminal elimination half-life (t1/2): levonorgestrel
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 56 to Day 68
Terminal elimination half-life (t1/2): ethinylestradiol
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 56 to Day 68
Terminal elimination half-life (t1/2): cenerimod
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 56 to Day 68
Area under the plasma concentration-time curve (AUC) from Day 56 to infinity (AUC56-inf) for cenerimod
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 56 to Day 68
Change from baseline in total lymphocyte count to each time point
Blood samples (fasting) collected at predefined time points as part of the normal hematology analysis.
Time frame: Day 5, Day 7, Day 14, Day 21, Day 35, Day 56, Day 57, Day 58, Day 1, Day 64, and Day 67
Maximum plasma concentration (Cmax): cenerimod
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 7, Day 14, Day 21, Day 35, and Day 56
Time to reach Cmax (tmax): cenerimod
Blood samples for determination of pharmacokinetic parameters will be collected at multiple predefined time points.
Time frame: Day 7, Day 14, Day 21, Day 35, and Day 56
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2020 to primary completion in Sep 2021, 19 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Contraceptives, Oral, Combined · Moxifloxacin · Cenerimod